Autolus Therapeutics Q1 Earnings Call Highlights

Autolus Therapeutics Q1 Earnings Call Highlights Autolus Therapeutics logo MarketBeat May 14, 2026 6 min read AUTL Key Points Interested in Autolus Therapeutics PLC Sponsored ADR? Here are five stocks we like better. Autolus Therapeutics said first-quarter 2026 product revenue rose to $26.2 million, driven by early traction for AUCATZYL in the U.S. and U.K., and it reaffirmed full-year revenue guidance of $120 million to $135 million.

The company reported a positive gross margin for the quarter and expects manufacturing efficiency gains to support further improvement, targeting a 65% to 70% gross profit margin in its peak adult ALL business. Autolus ended the quarter with GBP 229.4 million in cash and investments and said its current resources, including anticipated AUCATZYL revenue, should fund operations into the fourth quarter of 2027. Autolus Therapeutics (NASDAQ:AUTL) reported higher first-quarter 2026 product revenue and said its commercial launch of AUCATZYL is gaining traction in the U.S. and U.K., while reiterating full-year revenue guidance for the cell therapy.

Chief Executive Officer Dr. Christian Itin said the company had a "very good first quarter," with $26.2 million in revenue booked. He said Autolus is seeing "nice traction building" in the U.S. and in the early stages of its U.K. launch, where more than 10 centers are already active under the NHS access program. → Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe?

Autolus maintained its 2026 guidance for AUCATZYL net product revenue of $120 million to $135 million, including contributions from the U.S. and U.K. markets. Itin said the company has about 73 U.S. centers active and expects to increase that number beyond 80 by the end of the year. Gross Margin Turns Positive Chief Financial Officer Rob Dolski said total net product revenue for the first quarter was $26.2 million, compared with $9 million in the first quarter of 2025.

He said the quarter reflected U.S. sales and Autolus' first quarter in the U.K. market, though the U.K. contribution was minimal because the launch is still early. → MP Materials Is Quietly Building a Rare Earth Powerhouse The company shifted to a positive gross margin in the quarter, with $1.6 million, compared with losses in prior quarters of 2025. Dolski said cost of sales totaled GBP 24.6 million, compared with GBP 18 million in the same period last year, primarily reflecting higher AUCATZYL sales. Itin said gross margin improvement was driven by higher volume and operational changes, particularly at the company's manufacturing plant.

He said Autolus expects to produce twice as much product this year as last year with staffing "at or below" last year's levels. Story Continues → Micron Investors Face a High-Stakes Moment After the Latest Rally Itin said the company is targeting a 65% to 70% gross profit margin for the peak adult acute lymphoblastic leukemia, or ALL, business. In response to an analyst question, he said the company expects the ALL business to cross into profitability in 2028, though companywide profitability will depend on reinvestment levels.